Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
Myeloid Therapeutics
Novartis
Nurix Therapeutics, Inc.
Guardant Health, Inc.
Xencor, Inc.
Context Therapeutics Inc.
Telix Pharmaceuticals (Innovations) Pty Limited
PharmaMar
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc.
University of Chicago
Instituto do Cancer do Estado de São Paulo
Klus Pharma Inc.
Theratechnologies
Exelixis
Pfizer
Stanford University
EpicentRx, Inc.
Cybrexa Therapeutics
Carisma Therapeutics Inc
Salubris Biotherapeutics Inc
Hoffmann-La Roche
Eli Lilly and Company
Instil Bio
BioEclipse Therapeutics
Multitude Therapeutics Inc.
Pfizer
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
Xencor, Inc.
MacroGenics
Gilead Sciences
Abramson Cancer Center at Penn Medicine
City of Hope Medical Center
Swiss Cancer Institute
University of Washington
Pfizer
National Cancer Institute (NCI)
University of Washington
Wake Forest University Health Sciences
Dana-Farber Cancer Institute
University of Southern California
NewVac LLC
University of Arizona
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Washington
INSYS Therapeutics Inc